- Home
- ADEA vs GLPG Comparison
ADEA vs GLPG Comparison
Compare ADEA & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ADEA | GLPG |
|---|---|---|
| Founded | 1990 | 1999 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.1B |
| IPO Year | N/A | 2005 |
Fundamental Metrics
Financial Performance| Metric | ADEA | GLPG |
|---|---|---|
| Price | $17.54 | $32.95 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 4 |
| Target Price | $22.50 | ★ $31.33 |
| AVG Volume (30 Days) | ★ 1.0M | 83.6K |
| Earning Date | 02-17-2026 | 02-11-2026 |
| Dividend Yield | ★ 1.16% | N/A |
| EPS Growth | ★ 75.65 | N/A |
| EPS | ★ 0.65 | N/A |
| Revenue | ★ $379,912,000.00 | $336,643,201.00 |
| Revenue This Year | N/A | $1.76 |
| Revenue Next Year | $10.13 | $0.49 |
| P/E Ratio | $26.53 | ★ N/A |
| Revenue Growth | ★ 10.53 | 10.31 |
| 52 Week Low | $10.59 | $22.36 |
| 52 Week High | $18.25 | $37.78 |
Technical Indicators
Market Signals| Indicator | ADEA | GLPG |
|---|---|---|
| Relative Strength Index (RSI) | 71.70 | 60.36 |
| Support Level | $16.59 | $32.42 |
| Resistance Level | $17.88 | $33.37 |
| Average True Range (ATR) | 0.66 | 0.63 |
| MACD | 0.44 | 0.10 |
| Stochastic Oscillator | 88.57 | 86.39 |
Price Performance
Historical ComparisonAbout ADEA Adeia Inc.
Adeia Inc is a consumer and entertainment product/solutions licensing company. Its only operating segment being Intellectual Property (IP) Licensing. In the IP segment, the company licenses innovations to companies in the broader entertainment industry, and those developing new technologies that will help drive this industry forward. It includes Pay-TV, Consumer Electronics, Connected Car, and Media Platform.
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.